Glioblastoma therapy: State of the field and future prospects

Glioblastoma (GB) is a cancerous brain tumor that originates from glial cells and leads to thousands of deaths each year and a five-year survival of only 6.8 %. Treatments for GB include surgery, chemotherapy, radiation, and immunotherapy. GB is an incurable fatal disease, necessitating the developm...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2024-12, Vol.359, p.123227, Article 123227
Main Authors: Khiabani, Nadia Allahyarzadeh, Doustvandi, Mohammad Amin, Story, Darren, Nobari, Shima Alizadeh, Hajizadeh, Masoumeh, Petersen, Robert, Dunbar, Gary, Rossignol, Julien
Format: Article
Language:English
Subjects:
Animals
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Cancer stem cells
Gene Silencing
Genetic Therapy - methods
Glioblastoma
Glioblastoma - genetics
Glioblastoma - pathology
Glioblastoma - therapy
Humans
RNA, Small Interfering - genetics
Small interfering RNA (siRNA)
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma (GB) is a cancerous brain tumor that originates from glial cells and leads to thousands of deaths each year and a five-year survival of only 6.8 %. Treatments for GB include surgery, chemotherapy, radiation, and immunotherapy. GB is an incurable fatal disease, necessitating the development of innovative strategies to find a developing effective therapy. Genetic therapies may be crucial in treating GB by identifying the mutations and amplifications of multiple genes, which drive its proliferation and spread. Use of small interfering RNAs (siRNAs) provides a novel technology used to suppress the genes associated with disease, which forms a basis for targeted therapy in GB and its stem cell population, which are recognized for their ability to develop resistance to chemotherapy and tumorigenic capabilities. This review examines the use of siRNAs in GB, emphasizing their effectiveness in suppressing key oncogenes and signaling pathways associated with tumor development, invasion, stemness, and resistance to standard treatments. siRNA-based gene silencing is a promising approach for developing targeted therapeutics against GB and associated stem cell populations, potentially enhancing patient outcomes and survival rates in this devastating disease. [Display omitted]
ISSN:0024-3205
1879-0631
1879-0631
DOI:10.1016/j.lfs.2024.123227